Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial, Stock Up

(RTTNews) - Senti Biosciences, Inc. (SNTI), Tuesday announced new data from its ongoing trial of SENTI-202, evaluating the safety, efficacy, and pharmacodynamics of the treatment, when administered after Fludarabine/lymphodepletion in patients with relapsed or refractory Acute Myeloid Leukemia.

The findings revealed that 50 percent of patients at the Recommended Phase 2 Dose or RP2D, and 50 percent of all trial patients achieved an Overall Response Rateoutcome.

Meanwhile, 42 percent of patients at the RP2D and 39 percent of all patients overall achieved a Complete Remission or Complete Remission with Partial Hematologic Recovery.

Notably, SENTI-202 was detected in the peripheral blood of all patients, with pharmacokinetics that were consistent with other allogeneic NK cell therapies.

Currently, SNTI is trading at $2.58, up 8.27 percent on the Nasdaq.